CSIMarket Company Name, Ticker, Industry, else..
 
Rapport Therapeutics Inc   (NASDAQ: RAPP)
 
Price: $32.1700 $-0.66 -2.010%
Day's High: $34.47999954223633 Week Perf: -3.8 %
Day's Low: $ 31.77 30 Day Perf: -33.93 %
Volume (M): 275,738 52 Wk High: $ 52.93
Volume (M$): $ 0 52 Wk Avg: $34.04
Open: $33.33 52 Wk Low: $23.75



 Market Capitalization (Millions $) 1,527
 Shares Outstanding (Millions) 47
 Employees 84
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -137
 Cash Flow (TTM) (Millions $) 23
 Capital Exp. (TTM) (Millions $) 0

Business Description




   Company Address: 99 High Street Boston 2110 MA
   Company Phone Number: 321-8020   Stock Exchange / Ticker: NASDAQ RAPP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Navigating New Frontiers Rapport Therapeutics’ $250 Million Public Offering to Uphold Treatment for Neurol...

Published Wed, Sep 10 2025 4:01 AM UTC

On September 9, 2025, Rapport Therapeutics, Inc., a burgeoning clinical-stage biotechnology firm focused on developing small molecule precision medicines for neurological and psychiatric disorders, announced a significant public stock offering. This article assesses the content of the announcement, the implications for the company, and the broader impact on the biotechnology...
Clinical Study

Breaking Barriers in Neurology RAP-219s Promising Voyage for Seizure Control and Beyond,

Published Mon, Sep 8 2025 10:09 AM UTC

Recent developments in the clinical evaluation of RAP-219, an investigational treatment targeting focal onset seizures and central nervous system (CNS) disorders, have shown significant promise. Rapport Therapeutics has disclosed positive topline results from their Phase 2a clinical trial, underscoring RAP-219 s potential to transform treatment protocols for patients dealing...
Clinical Study

Hope on the Horizon Rapport Therapeutics Completes Enrollment in Landmark Trial for Refractory Focal Epilepsy Treat...

Published Mon, Jun 2 2025 8:20 PM UTC

In a recent Investor and Analyst Day, Rapport Therapeutics made noteworthy strides in its ongoing commitment to advancing treatments for neurological disorders, particularly refractory focal epilepsy. The company announced that it has successfully enrolled all participants in its Phase 2a clinical trial of RAP219, a novel therapeutic candidate aimed at addressing this challe...
Clinical Study

Rapport Therapeutics Inc has recently made significant strides in the realm of pharmaceutical d...

Published Fri, Dec 6 2024 5:01 PM UTC

Title : Rapport Therapeutics: Promising Advances in Seizure Management Amid Financial Challenges:Rapport Therapeutics Inc has recently made significant strides in the realm of pharmaceutical development, particularly regarding managing seizures. In a recent presentation, the company unveiled data indicating a consistent association between decreases in Resting Neurophysiolog...
Clinical Study

Advancements in Seizure Biomarkers Insights from Rapport Therapeutics’ Phase 2a and Preclinical Trials

Published Thu, Nov 14 2024 12:01 PM UTC

Rapport Therapeutics recently announced plans to present data at the American Epilepsy Society Annual Meeting, focusing on the outcomes of their Phase 2a trial, as well as preclinical and Phase 1 clinical data associated with seizure biomarkers. This article aims to outline the key findings and implications of these studies, which may provide significant advancements in the...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 76.36
Price to Sales (Expected) -
Price to Book 3.61
PEG (TTM) -

Financial Strength Current
Quick Ratio 15.34
Working Capital Ratio 15.73
Leverage Ratio (MRQ) 0.09
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.19 $
Revenues (TTM) 0.42 $
Cash Flow (TTM) 0.48 $
Cash 9.19 $
Book Value 8.91 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,632,857
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.